HSBC Holdings’s Ascendis Pharma A/S ASND Stock Holding History

HSBC Holdings’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$466K	Buy	+1,732	New	+$405K	﹤0.01%	2314
2025 Q2	–	Sell	-4,378	Closed	-$661K	–	3028
2025 Q1	$661K	Buy	+4,378	New	+$625K	﹤0.01%	1943
2024 Q2	–	Sell	-1,448	Closed	-$219K	–	2936
2024 Q1	$219K	Sell	1,448 -109,659	-99%	-$15.7M	﹤0.01%	2637
2023 Q4	$14.1M	Buy	+111,107	New	+$11.1M	0.01%	774

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

HSBC Holdings's ASND Position: Q2 2026 in Review

HSBC Holdings opened a new position in Ascendis Pharma A/S (ASND) in Q2 2026: 1,732 shares worth $466K. The stake represents ﹤0.01% of the portfolio and ranks #2314 among its holdings. This is a return to the name: HSBC Holdings previously reported a position in ASND as recently as Q1 2025.

HSBC Holdings first reported a position in ASND in Q4 2023 and has held it in 4 quarters since. The position peaked at $14.1M in Q4 2023. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

HSBC Holdings held 1,732 shares of Ascendis Pharma A/S worth $466K as of Q2 2026.
Ascendis Pharma A/S was a new HSBC Holdings position in Q2 2026.
Ascendis Pharma A/S made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #2314 holding.
HSBC Holdings first reported a position in Ascendis Pharma A/S in Q4 2023 and has held it in 4 quarters since.
HSBC Holdings's Ascendis Pharma A/S position peaked at $14.1M in Q4 2023.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.